Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT) (NCT02169505)
The goal of this clinical research study is to study the safety of brentuximab vedotin (also known as SGN-035; Adcetris®, Seattle Genetics) in patients with Hodgkin lymphoma or anaplastic large cell lymphoma (ALCL) who have had an allogeneic stem cell transplant. Another goal of this study is to learn if brentuximab vedotin can help to prevent the disease from coming back.
This trial is sponsored by M.D. Anderson Cancer Center. 
- Condition: Lymphoma
- Phase: II
- Estimated Enrollment: 20
- Start: May 2015
- Estimated Primary Completion: May 2018
- Last verified: June 2015
Last Editorial review: July 15, 2016
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.
Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.